Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Resource Type

CF Research News

Authors

Phuan PW, Son JH, Tan JA, Li C, Musante I, Zlock L, Nielson DW, Finkbeiner WE, Kurth MJ, Galietta LJ, Haggie PM, Verkman AS

References

J Cyst Fibros. 2018 Jun 11. pii: S1569-1993(18)30592-7. doi: 10.1016/j.jcf.2018.05.010.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

CFTR [3]
High-throughput screen [4]
N1303K [5]
Potentiator [6]

Date

Monday, June 11, 2018

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [7]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/combination-potentiator-co-potentiator-therapy-cf-caused-cftr

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-18-00074R2_FINAL_Phuan_090618.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/29903467 [3] https://www.ecfs.eu/research-article-keywords/cftr [4] https://www.ecfs.eu/research-article-keywords/high-throughput-screen [5] https://www.ecfs.eu/research-article-keywords/n1303k [6] https://www.ecfs.eu/research-article-keywords/potentiator [7] https://www.ecfs.eu/resource-guideline-type/other-guidelines